Molnupiravir's authorisation should be re-evaluated after the Panoramic trial is reported. | BMJ;377: o973, 2022 04 26. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Molnupiravir's authorisation should be re-evaluated after the Panoramic trial is reported.

Hill, Andrew.

Hill A; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3GF, UK.

BMJ ; 377: o973, 2022 04 26.

Article in English | MEDLINE | ID: covidwho-1825250

Subject(s)

Drug Approval; Cytidine/analogs & derivatives; Humans; Hydroxylamines

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug Approval Type of study: Experimental Studies / Randomized controlled trials Limits: Humans Language: English Journal: BMJ Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: Bmj.o973

Similar

MEDLINE

LILACS

LIS

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug Approval Type of study: Experimental Studies / Randomized controlled trials Limits: Humans Language: English Journal: BMJ Journal subject: Medicine Year: 2022 Document Type: Article Affiliation country: Bmj.o973